Lifitegrast
SHP606-304
Phase 3 small_molecule completed
Quick answer
Lifitegrast for Dry Eye Disease is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Dry Eye Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed